Market Overview

UPDATE: Deutsche Bank Initiates Coverage on Achillion Pharmaceuticals with Buy Rating, $12 PT

Related ACHN
Achillion Announces Janssen Initiated Phase I Study to Evaluate Effect of Simeprevir and Odalasvir on AL-335 Pharmacokinetics
Morning Market Losers

In a report published Wednesday, Deutsche Bank initiated coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Buy rating and $12.00 price target.

Deutsche Bank noted, “In spite of challenges in HCV, no one is losing interest in the space from speaking to ACHN management. As mentioned in Bloomberg on 8/28/12, many big pharma companies have interest in ACHN. We think acquirers range from current HCV developers to white space players not in HCV. They will want MORE safety in light of recent setbacks & likely lower takeout premiums...Our $12 TP is based on a probability adjusted DCF analysis. We assign 12% discount rate which is a 4.6% premium to our WACC, and terminal growth rate of -100% (no value post patent expiration). Main downside risks include 1) efficacy or safety concerns on NS5A/PI 2) Increased market competition 3) Delays in progress of clinical trial.”

Achillion Pharmaceuticals closed on Tuesday at $8.10.

Latest Ratings for ACHN

Aug 2015Maxim GroupMaintainsBuy
May 2015William BlairUpgradesMarket PerformOutperform
May 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings


Related Articles (ACHN)

Get Benzinga's Newsletters